PMID- 23065739
OWN - NLM
STAT- MEDLINE
DCOM- 20130521
LR  - 20151119
IS  - 1615-9861 (Electronic)
IS  - 1615-9853 (Linking)
VI  - 12
IP  - 23-24
DP  - 2012 Dec
TI  - Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel 
      for pancreatic ductal adenocarcinoma.
PG  - 3590-7
LID - 10.1002/pmic.201200101 [doi]
AB  - Pancreatic ductal adenocarcinoma (PDAC) accounts for 95% of pancreatic cancers. 
      CA19-9 is not widely used for screening PDAC due to its low sensitivity. Here, we 
      studied the clinical usefulness of cathepsin D, matrix metalloproteinases (MMPs), 
      and tissue inhibitors of MMPs (TIMPs) for screening patients with PDAC. A total 
      of 248 patients with PDAC and 216 control subjects were recruited (109 PDAC 
      patients and 70 controls in the training set and 139 PDAC patients and 146 
      controls in the validation set). We measured serum levels of cathepsin D, TIMPs 
      (-1, -3, and -4), and MMPs (-1, -7, -8, and -9) using Fluorokine MAP multiplex 
      kits. The concentrations of cathepsin D and MMP-7 were significantly higher in 
      PDAC subjects than control subjects. In the training set, the diagnostic 
      sensitivity and AUC of the panel of CA19-9, cathepsin D, and MMP-7 for PDAC were 
      increased to 88% and 0.900, compared to 74% and 0.835 of CA19-9 single marker at 
      80% specificity. The sensitivity using cut-off value of biomarker panel was 
      significantly increased in the validation set as well as training set. Our 
      findings indicate that a serum biomarker panel consisting of CA19-9, cathepsin D, 
      and MMP-7 may provide the most effective screening test currently feasible for 
      PDAC.
CI  - (c) 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
FAU - Park, Hyung-Doo
AU  - Park HD
AD  - Department of Laboratory Medicine and Genetics, Samsung Medical Center, 
      Sungkyunkwan University School of Medicine, Seoul, Korea.
FAU - Kang, Eun-Suk
AU  - Kang ES
FAU - Kim, Jong-Won
AU  - Kim JW
FAU - Lee, Kyu-Taek
AU  - Lee KT
FAU - Lee, Kwang Hyuck
AU  - Lee KH
FAU - Park, Young Suk
AU  - Park YS
FAU - Park, Joon-Oh
AU  - Park JO
FAU - Lee, Jeeyun
AU  - Lee J
FAU - Heo, Jin Seok
AU  - Heo JS
FAU - Choi, Seong Ho
AU  - Choi SH
FAU - Choi, Dong Wook
AU  - Choi DW
FAU - Kim, Seonwoo
AU  - Kim S
FAU - Lee, Jong Kyun
AU  - Lee JK
FAU - Lee, Soo-Youn
AU  - Lee SY
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Proteomics
JT  - Proteomics
JID - 101092707
RN  - 0 (CA-19-9 Antigen)
RN  - EC 3.4.23.5 (Cathepsin D)
RN  - EC 3.4.24.23 (Matrix Metalloproteinase 7)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - CA-19-9 Antigen/*blood
MH  - Carcinoma, Pancreatic Ductal/blood/*diagnosis
MH  - Cathepsin D/*blood
MH  - Female
MH  - Humans
MH  - Male
MH  - Matrix Metalloproteinase 7/*blood
MH  - Middle Aged
MH  - Pancreatic Ducts/pathology
MH  - Pancreatic Neoplasms/blood/*diagnosis
EDAT- 2012/10/16 06:00
MHDA- 2013/05/23 06:00
CRDT- 2012/10/16 06:00
PHST- 2012/03/06 00:00 [received]
PHST- 2012/09/06 00:00 [revised]
PHST- 2012/09/20 00:00 [accepted]
PHST- 2012/10/16 06:00 [entrez]
PHST- 2012/10/16 06:00 [pubmed]
PHST- 2013/05/23 06:00 [medline]
AID - 10.1002/pmic.201200101 [doi]
PST - ppublish
SO  - Proteomics. 2012 Dec;12(23-24):3590-7. doi: 10.1002/pmic.201200101.